A Statistical Study on Survival Analysis for Cancer Disease with Failure Time

biomedical applications, especially in clinical trials, two important issues arise when studying time to event data: (i) some individuals are still alive at the end of the study or analysis so the event of interest, namely death, has not occurred. Therefore we have right censored data. (ii) Length of follow-up varies due to staggered entry. So we cannot observe the event for those individuals with insufficient follow-up time. In addition to censoring because of insufficient follow-up (i.e., end of study censoring due to staggered entry), other reasons for censoring includes (a) loss to follow-up: patients stop coming to clinic or move away, (b) deaths from other causes: competing risks (Altman, 1982). Censoring from these types of causes may be inherently different from censoring due to staggered entry. In this research provided that the analysis of survival time for clinical trial with suitable data.